Literature DB >> 20937792

Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges.

Claudia Lengerke, Michael Haap, Frank Mayer, Lothar Kanz, Martina Kinzig, Ulrike Schumacher, Fritz Sörgel, Reimer Riessen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20937792      PMCID： PMC3019631          DOI： 10.1128/AAC.00635-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.

Authors:  Keith A Rodvold; Mark H Gotfried; Michael Cwik; Joan M Korth-Bradley; Gary Dukart; Evelyn J Ellis-Grosse
Journal:  J Antimicrob Chemother       Date:  2006-09-29       Impact factor: 5.790

Review 2.  Tigecycline.

Authors:  George A Pankey
Journal:  J Antimicrob Chemother       Date:  2005-07-22       Impact factor: 5.790

3.  Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem.

Authors:  María Eugenia Pachón-Ibáñez; Manuel Enrique Jiménez-Mejías; Cristina Pichardo; Ana Cristina Llanos; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 4.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

5.  Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.

Authors:  Ken B Waites; Lynn B Duffy; Michael J Dowzicky
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

6.  In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

Authors:  Daryl J Hoban; Samuel K Bouchillon; Brian M Johnson; Jack L Johnson; Michael J Dowzicky
Journal:  Diagn Microbiol Infect Dis       Date:  2005-07       Impact factor: 2.803

7.  Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline.

Authors:  Heather B Jaspan; Adam W Brothers; Angela J P Campbell; John K McGuire; Samuel R Browd; Thomas J Manley; Daniel Pak; Scott J Weissman
Journal:  Pediatr Infect Dis J       Date:  2010-04       Impact factor: 2.129

8.  In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay.

Authors:  George A Pankey; Deborah S Ashcraft
Journal:  Diagn Microbiol Infect Dis       Date:  2009-07       Impact factor: 2.803

9.  Population pharmacokinetics of tigecycline in healthy volunteers.

Authors:  S A Van Wart; B B Cirincione; E A Ludwig; A K Meagher; J M Korth-Bradley; J S Owen
Journal:  J Clin Pharmacol       Date:  2007-06       Impact factor: 3.126

10.  Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline.

Authors:  Jamal Ahmad Wadi; Mohammad Abu Al Rub
Journal:  Ann Saudi Med       Date:  2007 Nov-Dec       Impact factor: 1.526
View more
  5 in total

Review 1.  Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Menino Osbert Cotta
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

Review 3.  Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment.

Authors:  Divine C Nwafor; Allison L Brichacek; Afroz S Mohammad; Jessica Griffith; Brandon P Lucke-Wold; Stanley A Benkovic; Werner J Geldenhuys; Paul R Lockman; Candice M Brown
Journal:  J Cent Nerv Syst Dis       Date:  2019-04-09

4.  Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Ozioma F Nwabor; Pawarisa Terbtothakun; Supayang P Voravuthikunchai; Sarunyou Chusri
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-25

5.  Intravenous plus intraventricular tigecycline-amikacin therapy for the treatment of carbapenem-resistant Klebsiella pneumoniae ventriculitis: A case report.

Authors:  Jiyao Li; Yiguo Liu; Guangtao Wu; Hongyan Wang; Xiaoyan Xu
Journal:  Medicine (Baltimore)       Date:  2022-07-29       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.